AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
190.86
-0.22 (-0.12%)
At close: Jun 16, 2025, 4:00 PM
190.92
+0.06 (0.03%)
After-hours: Jun 16, 2025, 7:57 PM EDT
AbbVie Employees
AbbVie had 55,000 employees as of December 31, 2024. The number of employees increased by 5,000 or 10.00% compared to the previous year.
Employees
55,000
Change (1Y)
5,000
Growth (1Y)
10.00%
Revenue / Employee
$1,043,036
Profits / Employee
$75,545
Market Cap
337.14B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ABBV News
- 14 hours ago - AbbVie says blood cancer drug fails late-stage trial - Reuters
- 15 hours ago - AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes - PRNewsWire
- 19 hours ago - AbbVie: Margin Clarity, Dividend Durability Awaited - Seeking Alpha
- 22 hours ago - AbbVie Moves From Blockbuster Loss To Market Domination - Seeking Alpha
- 1 day ago - AbbVie: A Biotech Powerhouse Generating Explosive EPS And Dividend Growth - Seeking Alpha
- 1 day ago - AbbVie's Post-Humira Strategy Is Paying Off For Investors - Seeking Alpha
- 4 days ago - Giant-Cell Arteritis Market Heats up with AbbVie's RINVOQ Approval | DelveInsight - GlobeNewsWire
- 5 days ago - U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus - PRNewsWire